Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Identifieur interne : 003639 ( Main/Exploration ); précédent : 003638; suivant : 003640Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Auteurs : Robert J. Motzer [Suisse] ; Carlos H. Barrios [Suisse] ; Tae Min Kim [Suisse] ; Silvia Falcon [Suisse] ; Thomas Cosgriff [Suisse] ; W. Graydon Harker [Suisse] ; Vichien Srimuninnimit [Suisse] ; Ken Pittman [Suisse] ; Roberto Sabbatini [Suisse] ; Sun Young Rha [Suisse] ; Thomas W. Flaig [Suisse] ; Ray Page [Suisse] ; Sevil Bavbek [Suisse] ; J. Thaddeus Beck [Suisse] ; Poulam Patel [Suisse] ; Foon-Yiu Cheung [Suisse] ; Sunil Yadav [Suisse] ; Edward M. Schiff [Suisse] ; Xufang Wang [Suisse] ; Julie Niolat [Suisse] ; Dalila Sellami [Suisse] ; Oezlem Anak [Suisse] ; Jennifer J. Knox [Suisse]Source :
- Journal of Clinical Oncology [ 0732-183X ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Indoles (administration et posologie), Jeune adulte, Mâle, Métastase tumorale, Néphrocarcinome (anatomopathologie), Néphrocarcinome (traitement médicamenteux), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Pyrroles (administration et posologie), Résultat thérapeutique, Sirolimus (administration et posologie), Sirolimus (analogues et dérivés), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs du rein (anatomopathologie), Tumeurs du rein (traitement médicamenteux), Études croisées, Évérolimus.
- MESH :
- administration et posologie : Indoles, Protocoles de polychimiothérapie antinéoplasique, Pyrroles, Sirolimus.
- analogues et dérivés : Sirolimus.
- anatomopathologie : Néphrocarcinome, Tumeurs du rein.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Métastase tumorale, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Études croisées, Évérolimus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (pathology), Cross-Over Studies, Disease-Free Survival, Drug Administration Schedule, Everolimus, Female, Humans, Indoles (administration & dosage), Kidney Neoplasms (drug therapy), Kidney Neoplasms (pathology), Male, Middle Aged, Neoplasm Metastasis, Pyrroles (administration & dosage), Sirolimus (administration & dosage), Sirolimus (analogs & derivatives), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Indoles, Pyrroles, Sirolimus.
- chemical , analogs & derivatives : Sirolimus.
- chemical : Everolimus.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- pathology : Carcinoma, Renal Cell, Kidney Neoplasms.
- Adult, Aged, Aged, 80 and over, Cross-Over Studies, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Treatment Outcome, Young Adult.
Abstract
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma.
RECORD-3 used a crossover treatment design. The primary objective was to assess progression-free survival (PFS) noninferiority of first-line everolimus compared with first-line sunitinib. Secondary end points included combined PFS for each sequence, overall survival (OS), and safety.
Of 471 enrolled patients, 238 were randomly assigned to first-line everolimus followed by sunitinib, and 233 were randomly assigned to first-line sunitinib followed by everolimus. The primary end point was not met; the median PFS was 7.9 months for first-line everolimus and 10.7 months for first-line sunitinib (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.8). Among patients who discontinued first-line, 108 (45%) crossed over from everolimus to second-line sunitinib, and 99 (43%) crossed over from sunitinib to second-line everolimus. The median combined PFS was 21.1 months for sequential everolimus then sunitinib and was 25.8 months for sequential sunitinib then everolimus (HR, 1.3; 95% CI, 0.9 to 1.7). The median OS was 22.4 months for sequential everolimus and then sunitinib and 32.0 months for sequential sunitinib and then everolimus (HR, 1.2; 95% CI, 0.9 to 1.6). Common treatment-emergent adverse events during first-line everolimus or sunitinib were stomatitis (53% and 57%, respectively), fatigue (45% and 51%, respectively), and diarrhea (38% and 57%, respectively).
Everolimus did not demonstrate noninferiority compared with sunitinib as a first-line therapy. The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression.
Url:
DOI: 10.1200/JCO.2013.54.6911
PubMed: 25049330
PubMed Central: 5569681
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001957
- to stream Pmc, to step Curation: 001816
- to stream Pmc, to step Checkpoint: 001411
- to stream PubMed, to step Corpus: 003510
- to stream PubMed, to step Curation: 003397
- to stream PubMed, to step Checkpoint: 003397
- to stream Ncbi, to step Merge: 001C46
- to stream Ncbi, to step Curation: 001C46
- to stream Ncbi, to step Checkpoint: 001C46
- to stream Main, to step Merge: 003658
- to stream Main, to step Curation: 003639
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma</title><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J." last="Motzer">Robert J. Motzer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H." last="Barrios">Carlos H. Barrios</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Tae Min" sort="Kim, Tae Min" uniqKey="Kim T" first="Tae Min" last="Kim">Tae Min Kim</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Falcon, Silvia" sort="Falcon, Silvia" uniqKey="Falcon S" first="Silvia" last="Falcon">Silvia Falcon</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Cosgriff, Thomas" sort="Cosgriff, Thomas" uniqKey="Cosgriff T" first="Thomas" last="Cosgriff">Thomas Cosgriff</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Harker, W Graydon" sort="Harker, W Graydon" uniqKey="Harker W" first="W. Graydon" last="Harker">W. Graydon Harker</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Srimuninnimit, Vichien" sort="Srimuninnimit, Vichien" uniqKey="Srimuninnimit V" first="Vichien" last="Srimuninnimit">Vichien Srimuninnimit</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Pittman, Ken" sort="Pittman, Ken" uniqKey="Pittman K" first="Ken" last="Pittman">Ken Pittman</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sabbatini, Roberto" sort="Sabbatini, Roberto" uniqKey="Sabbatini R" first="Roberto" last="Sabbatini">Roberto Sabbatini</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W." last="Flaig">Thomas W. Flaig</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Page, Ray" sort="Page, Ray" uniqKey="Page R" first="Ray" last="Page">Ray Page</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bavbek, Sevil" sort="Bavbek, Sevil" uniqKey="Bavbek S" first="Sevil" last="Bavbek">Sevil Bavbek</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Beck, J Thaddeus" sort="Beck, J Thaddeus" uniqKey="Beck J" first="J. Thaddeus" last="Beck">J. Thaddeus Beck</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Patel, Poulam" sort="Patel, Poulam" uniqKey="Patel P" first="Poulam" last="Patel">Poulam Patel</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Cheung, Foon Yiu" sort="Cheung, Foon Yiu" uniqKey="Cheung F" first="Foon-Yiu" last="Cheung">Foon-Yiu Cheung</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Yadav, Sunil" sort="Yadav, Sunil" uniqKey="Yadav S" first="Sunil" last="Yadav">Sunil Yadav</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Schiff, Edward M" sort="Schiff, Edward M" uniqKey="Schiff E" first="Edward M." last="Schiff">Edward M. Schiff</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Xufang" sort="Wang, Xufang" uniqKey="Wang X" first="Xufang" last="Wang">Xufang Wang</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Niolat, Julie" sort="Niolat, Julie" uniqKey="Niolat J" first="Julie" last="Niolat">Julie Niolat</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sellami, Dalila" sort="Sellami, Dalila" uniqKey="Sellami D" first="Dalila" last="Sellami">Dalila Sellami</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Anak, Oezlem" sort="Anak, Oezlem" uniqKey="Anak O" first="Oezlem" last="Anak">Oezlem Anak</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J." last="Knox">Jennifer J. Knox</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25049330</idno><idno type="pmc">5569681</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569681</idno><idno type="RBID">PMC:5569681</idno><idno type="doi">10.1200/JCO.2013.54.6911</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001957</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001957</idno><idno type="wicri:Area/Pmc/Curation">001816</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001816</idno><idno type="wicri:Area/Pmc/Checkpoint">001411</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001411</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">003510</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003510</idno><idno type="wicri:Area/PubMed/Curation">003397</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003397</idno><idno type="wicri:Area/PubMed/Checkpoint">003397</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003397</idno><idno type="wicri:Area/Ncbi/Merge">001C46</idno><idno type="wicri:Area/Ncbi/Curation">001C46</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C46</idno><idno type="wicri:doubleKey">0732-183X:2014:Motzer R:phase:ii:randomized</idno><idno type="wicri:Area/Main/Merge">003658</idno><idno type="wicri:Area/Main/Curation">003639</idno><idno type="wicri:Area/Main/Exploration">003639</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma</title><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J." last="Motzer">Robert J. Motzer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H." last="Barrios">Carlos H. Barrios</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Tae Min" sort="Kim, Tae Min" uniqKey="Kim T" first="Tae Min" last="Kim">Tae Min Kim</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Falcon, Silvia" sort="Falcon, Silvia" uniqKey="Falcon S" first="Silvia" last="Falcon">Silvia Falcon</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Cosgriff, Thomas" sort="Cosgriff, Thomas" uniqKey="Cosgriff T" first="Thomas" last="Cosgriff">Thomas Cosgriff</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Harker, W Graydon" sort="Harker, W Graydon" uniqKey="Harker W" first="W. Graydon" last="Harker">W. Graydon Harker</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Srimuninnimit, Vichien" sort="Srimuninnimit, Vichien" uniqKey="Srimuninnimit V" first="Vichien" last="Srimuninnimit">Vichien Srimuninnimit</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Pittman, Ken" sort="Pittman, Ken" uniqKey="Pittman K" first="Ken" last="Pittman">Ken Pittman</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sabbatini, Roberto" sort="Sabbatini, Roberto" uniqKey="Sabbatini R" first="Roberto" last="Sabbatini">Roberto Sabbatini</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W." last="Flaig">Thomas W. Flaig</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Page, Ray" sort="Page, Ray" uniqKey="Page R" first="Ray" last="Page">Ray Page</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bavbek, Sevil" sort="Bavbek, Sevil" uniqKey="Bavbek S" first="Sevil" last="Bavbek">Sevil Bavbek</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Beck, J Thaddeus" sort="Beck, J Thaddeus" uniqKey="Beck J" first="J. Thaddeus" last="Beck">J. Thaddeus Beck</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Patel, Poulam" sort="Patel, Poulam" uniqKey="Patel P" first="Poulam" last="Patel">Poulam Patel</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Cheung, Foon Yiu" sort="Cheung, Foon Yiu" uniqKey="Cheung F" first="Foon-Yiu" last="Cheung">Foon-Yiu Cheung</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Yadav, Sunil" sort="Yadav, Sunil" uniqKey="Yadav S" first="Sunil" last="Yadav">Sunil Yadav</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Schiff, Edward M" sort="Schiff, Edward M" uniqKey="Schiff E" first="Edward M." last="Schiff">Edward M. Schiff</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Xufang" sort="Wang, Xufang" uniqKey="Wang X" first="Xufang" last="Wang">Xufang Wang</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Niolat, Julie" sort="Niolat, Julie" uniqKey="Niolat J" first="Julie" last="Niolat">Julie Niolat</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sellami, Dalila" sort="Sellami, Dalila" uniqKey="Sellami D" first="Dalila" last="Sellami">Dalila Sellami</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Anak, Oezlem" sort="Anak, Oezlem" uniqKey="Anak O" first="Oezlem" last="Anak">Oezlem Anak</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J." last="Knox">Jennifer J. Knox</name><affiliation wicri:level="1"><nlm:aff id="aff1">Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel, Switzerland.</nlm:aff><country xml:lang="fr" wicri:curation="lc">Suisse</country><wicri:regionArea>Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY; Carlos H. Barrios, PUCRS School of Medicine, Porto Alegre, Brazil; Tae Min Kim, Seoul National University Hospital; and Sun Young Rha, Severance Hospital, Yonsei Cancer Center, Seoul, Korea; Silvia Falcon, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Thomas Cosgriff, Hematology and Oncology Specialists, Metairie, LA; Graydon Harker, Utah Cancer Specialists, Salt Lake City, UT; Vichien Srimuninnimit, Siriraj Hospital, Mahidol, Thailand; Ken Pittman, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Roberto Sabbatini, Azienda Ospedaliero Universitaria Policlinico di Modena, Italy; Thomas W. Flaig, University of Colorado Cancer Center, Aurora, CO; Ray Page, Center for Cancer and Blood Disorders, Fort Worth, TX; Sevil E. Bavbek, American Hospital, Istanbul, Turkey; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Poulam Patel, University of Nottingham, United Kingdom; Foon-yiu Cheung, Queen Elizabeth Hospital, Kowloon, Hong Kong; Sunil Yadav, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; and Jennifer J. Knox, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; Edward M. Schiff, Dalila Sellami, and Xufang Wang, Novartis Oncology, East Hanover, NJ; Julie Niolat, Novartis Pharma SAS, Rueil-Malmaison, France; and Oezlem Anak, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (pathology)</term><term>Cross-Over Studies</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Everolimus</term><term>Female</term><term>Humans</term><term>Indoles (administration & dosage)</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Pyrroles (administration & dosage)</term><term>Sirolimus (administration & dosage)</term><term>Sirolimus (analogs & derivatives)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Indoles (administration et posologie)</term><term>Jeune adulte</term><term>Mâle</term><term>Métastase tumorale</term><term>Néphrocarcinome (anatomopathologie)</term><term>Néphrocarcinome (traitement médicamenteux)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Pyrroles (administration et posologie)</term><term>Résultat thérapeutique</term><term>Sirolimus (administration et posologie)</term><term>Sirolimus (analogues et dérivés)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs du rein (anatomopathologie)</term><term>Tumeurs du rein (traitement médicamenteux)</term><term>Études croisées</term><term>Évérolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indoles</term><term>Pyrroles</term><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Everolimus</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Indoles</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyrroles</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Over Studies</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Métastase tumorale</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Études croisées</term><term>Évérolimus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma.</p></sec><sec><title>Patients and Methods</title><p>RECORD-3 used a crossover treatment design. The primary objective was to assess progression-free survival (PFS) noninferiority of first-line everolimus compared with first-line sunitinib. Secondary end points included combined PFS for each sequence, overall survival (OS), and safety.</p></sec><sec><title>Results</title><p>Of 471 enrolled patients, 238 were randomly assigned to first-line everolimus followed by sunitinib, and 233 were randomly assigned to first-line sunitinib followed by everolimus. The primary end point was not met; the median PFS was 7.9 months for first-line everolimus and 10.7 months for first-line sunitinib (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.8). Among patients who discontinued first-line, 108 (45%) crossed over from everolimus to second-line sunitinib, and 99 (43%) crossed over from sunitinib to second-line everolimus. The median combined PFS was 21.1 months for sequential everolimus then sunitinib and was 25.8 months for sequential sunitinib then everolimus (HR, 1.3; 95% CI, 0.9 to 1.7). The median OS was 22.4 months for sequential everolimus and then sunitinib and 32.0 months for sequential sunitinib and then everolimus (HR, 1.2; 95% CI, 0.9 to 1.6). Common treatment-emergent adverse events during first-line everolimus or sunitinib were stomatitis (53% and 57%, respectively), fatigue (45% and 51%, respectively), and diarrhea (38% and 57%, respectively).</p></sec><sec><title>Conclusion</title><p>Everolimus did not demonstrate noninferiority compared with sunitinib as a first-line therapy. The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression.</p></sec></div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J." last="Motzer">Robert J. Motzer</name></noRegion><name sortKey="Anak, Oezlem" sort="Anak, Oezlem" uniqKey="Anak O" first="Oezlem" last="Anak">Oezlem Anak</name><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H." last="Barrios">Carlos H. Barrios</name><name sortKey="Bavbek, Sevil" sort="Bavbek, Sevil" uniqKey="Bavbek S" first="Sevil" last="Bavbek">Sevil Bavbek</name><name sortKey="Beck, J Thaddeus" sort="Beck, J Thaddeus" uniqKey="Beck J" first="J. Thaddeus" last="Beck">J. Thaddeus Beck</name><name sortKey="Cheung, Foon Yiu" sort="Cheung, Foon Yiu" uniqKey="Cheung F" first="Foon-Yiu" last="Cheung">Foon-Yiu Cheung</name><name sortKey="Cosgriff, Thomas" sort="Cosgriff, Thomas" uniqKey="Cosgriff T" first="Thomas" last="Cosgriff">Thomas Cosgriff</name><name sortKey="Falcon, Silvia" sort="Falcon, Silvia" uniqKey="Falcon S" first="Silvia" last="Falcon">Silvia Falcon</name><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W." last="Flaig">Thomas W. Flaig</name><name sortKey="Harker, W Graydon" sort="Harker, W Graydon" uniqKey="Harker W" first="W. Graydon" last="Harker">W. Graydon Harker</name><name sortKey="Kim, Tae Min" sort="Kim, Tae Min" uniqKey="Kim T" first="Tae Min" last="Kim">Tae Min Kim</name><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J." last="Knox">Jennifer J. Knox</name><name sortKey="Niolat, Julie" sort="Niolat, Julie" uniqKey="Niolat J" first="Julie" last="Niolat">Julie Niolat</name><name sortKey="Page, Ray" sort="Page, Ray" uniqKey="Page R" first="Ray" last="Page">Ray Page</name><name sortKey="Patel, Poulam" sort="Patel, Poulam" uniqKey="Patel P" first="Poulam" last="Patel">Poulam Patel</name><name sortKey="Pittman, Ken" sort="Pittman, Ken" uniqKey="Pittman K" first="Ken" last="Pittman">Ken Pittman</name><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name><name sortKey="Sabbatini, Roberto" sort="Sabbatini, Roberto" uniqKey="Sabbatini R" first="Roberto" last="Sabbatini">Roberto Sabbatini</name><name sortKey="Schiff, Edward M" sort="Schiff, Edward M" uniqKey="Schiff E" first="Edward M." last="Schiff">Edward M. Schiff</name><name sortKey="Sellami, Dalila" sort="Sellami, Dalila" uniqKey="Sellami D" first="Dalila" last="Sellami">Dalila Sellami</name><name sortKey="Srimuninnimit, Vichien" sort="Srimuninnimit, Vichien" uniqKey="Srimuninnimit V" first="Vichien" last="Srimuninnimit">Vichien Srimuninnimit</name><name sortKey="Wang, Xufang" sort="Wang, Xufang" uniqKey="Wang X" first="Xufang" last="Wang">Xufang Wang</name><name sortKey="Yadav, Sunil" sort="Yadav, Sunil" uniqKey="Yadav S" first="Sunil" last="Yadav">Sunil Yadav</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003639 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003639 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5569681
|texte= Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25049330" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |